// App-Quantinova.ai

: Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients.

Researchers

Presenter

  • Ricardo Romao Nazario Leao

Principal Investigators

  • Ton Van Agthoven

  • Arnaldo Figueiredo

  • Kamel Fadaak

  • Pedro Castelo-Branco

  • Michael A.S. Jewett

  • Joan Sweet

  • Ardalan Ahmad

  • Lynn Anson-Cartwright

  • Philippe L. Bedard

  • Peter W. M. Chung

  • Aaron Richard Hansen

  • Padraig Richard Warde

  • Martin O'Malley

  • Leendert Looijenga

  • Robert James Hamilton

Medical Centers

  • Universtiy Health Network, Toronto, ON, Canada

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Centro Hospitalar Universitario de Coimbra (CHUC), Coimbra, Portugal.

  • Regenerative Medicine Program, University of Algarve, Faro, Portugal

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • University of Toronto, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved